Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma

Schmidt, Henrik; Johansen, Julia S.; Sjoegren, Pia; Christensen, Ib Jarle; Sørensen, Boe Sandahl; Fode, Kirsten; Larsen, Julie Brogaard; Maase, Hans von der

doi:10.1200/jco.2005.03.7960

Cited by 68 publications

(53 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of the elevations in serum YKL-40 reported in cancer patients (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(24)(25)(26) are not higher than could be explained by pre-analytic conditions and methodologic and normal biological variability, but in all types of cancer, some patients have much higher levels (Fig. 1).…”

Section: Discussionmentioning

confidence: 95%

“…Serum YKL-40 may be useful for monitoring disease recurrence or progression in cancer patients after treatment (13,14,(23)(24)(25). High serum YKL-40 during follow-up after curative operation for colorectal cancer (23) or stage I to II melanoma (14) were associated with short recurrence -free interval and short survival.…”

Section: Discussionmentioning

confidence: 99%

“…Serum YKL-40 is elevated compared with healthy subjects in many patients with primary or metastatic carcinoma of the breast (2), colorectal (3), ovary (4,5), lung (6), prostate (7), kidney (8), endometrial (9), cervical (10), and head and neck (11), and in patients with glioblastoma (12,13), melanoma (14,15), acute myeloid leukemia (16), and multiple myeloma (17). Figure 1 shows the distribution of serum YKL-40 in patients with different types of cancer, showing the range, median, and the percentage with elevated levels.…”

Section: Introductionmentioning

confidence: 99%

“…This was found in patients with local or metastatic cancer, at time of first cancer diagnosis and at time of relapse, and serum YKL-40 was independent of other biomarkers when tested in multivariate Cox analysis (e.g., estrogen receptor status, HER2, CEA, CA125, and LDH; refs. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

Johansen

Lottenburger

Nielsen

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Serum YKL-40 is a potential biomarker of prognosis in cancer patients, but assessment of serum YKL-40 requires knowledge of its normal variation. In this study, we evaluated diurnal, weekly, and long-term variation in serum YKL-40 in healthy subjects using a commercial ELISA. The intra-assay coefficient of variation was V5.0% and interassay V10.2%. Systematic changes in diurnal measurements of serum YKL-40 could not be shown. Physical exercise for 20 min had no effect on serum YKL-40. The within-subject coefficient of variation, including variation over time and interassay, was 28.8% and 30.2% over a period of 2 and 3 years, and the intraclass correlation coefficients were 72.4% and 72.2%, indicating reasonable reliability of serum YKL-40 measurements. The 95% confidence limits for the difference between two measurements (same subject), including interassay variation, were a 52% reduction and a 109% increase in serum YKL-40. These studies show that relatively small variation is found in serum YKL-40 in healthy subjects. However, a single measurement of serum YKL-40 from an individual may not have a prognostic value, and serum YKL-40 alone cannot be a good biomarker for cancer because serum YKL-40 can be elevated in patients with other diseases characterized by inflammation and tissue remodeling.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

Johansen

Lottenburger

Nielsen

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…The variability of survival in these stages indicates its heterogeneity, and so other prognostic factors (mitotic rate, serum YKL-40, PTEN, Ki67 expression, etc.) must be included to better discriminate different patient subgroups [7][8][9][10]. Stage III patients are also a very heterogeneous group, with high risk and worse prognosis as they always involve lymph node affectation where the number of affected nodes is an indicator of survival, with age, location, the presence of macro-or micrometastasis in the lymphatic nodes (67% versus 43% up to 5 years, < 0.001), and so forth also having an influence (Tables 2 and 3) [11,12].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant Treatment of Melanoma

Nogueira¹,

Valero²,

Moreno³

2011

Current Management of Malignant Melanoma

View full text Add to dashboard Cite

Melanomas represent 4% of all malignant tumors of the skin, yet account for 80% of deaths from skin cancer.While in the early stages patients can be successfully treated with surgical resection, metastatic melanoma prognosis is dismal. Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene. The treatment of choice for localised primary cutaneous melanoma is surgery plus lymphadenectomy if regional lymph nodes are involved. The justification for treatment in addition to surgery is based on the poor prognosis for high risk melanomas with a relapse index of 50-80%. Patients included in the high risk group should be assessed for adjuvant treatment with high doses of Interferon-2b, as it is the only treatment shown to significantly improve disease free and possibly global survival. In the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.

show abstract

YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma

Hottinger

Iwamoto

Karimi

et al. 2011

Annals of Neurology

View full text Add to dashboard Cite

show abstract

Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma

Abstract: Serum YKL-40 may be an early biomarker of relapse and survival in patients with AJCC stage I and II melanoma. Serum YKL-40 may also be useful for patient stratification and follow-up in clinical trials. Our results need confirmation in an independent study.

Cited by 68 publications

References 45 publications

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

Adjuvant Treatment of Melanoma

YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma

Contact Info

Product

Resources

About